journal
MENU ▼
Read by QxMD icon Read
search

Lancet Diabetes & Endocrinology

journal
https://www.readbyqxmd.com/read/29146206/using-big-data-for-non-communicable-disease-surveillance
#1
Ran D Balicer, Miguel Luengo-Oroz, Chandra Cohen-Stavi, Enrique Loyola, Frederiek Mantingh, Liudmyla Romanoff, Gauden Galea
No abstract text is available yet for this article.
November 13, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29129576/cardiometabolic-outcomes-and-mortality-in-medically-treated-primary-aldosteronism-a-retrospective-cohort-study
#2
Gregory L Hundemer, Gary C Curhan, Nicholas Yozamp, Molin Wang, Anand Vaidya
BACKGROUND: Mineralocorticoid receptor (MR) antagonists are the recommended medical therapy for primary aldosteronism. Whether this recommendation effectively reduces cardiometabolic risk is not well understood. We aimed to investigate the risk of incident cardiovascular events in patients with primary aldosteronism treated with MR antagonists compared with patients with essential hypertension. METHODS: We did a cohort study using patients from a research registry from Brigham and Women's Hospital, Massachusetts General Hospital, and their affiliated partner hospitals...
November 9, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29129575/cardiovascular-events-and-target-organ-damage-in-primary-aldosteronism-compared-with-essential-hypertension-a-systematic-review-and-meta-analysis
#3
Silvia Monticone, Fabrizio D'Ascenzo, Claudio Moretti, Tracy Ann Williams, Franco Veglio, Fiorenzo Gaita, Paolo Mulatero
BACKGROUND: There is conflicting evidence, relying on heterogeneous studies, as to whether aldosterone excess is responsible for an increased risk of cardiovascular and cerebrovascular complications in patients with primary aldosteronism. We aimed to assess the association between primary aldosteronism and adverse cardiac and cerebrovascular events, target organ damage, diabetes, and metabolic syndrome, compared with the association of essential hypertension and these cardiovascular and end organ events, by integrating results of previous studies...
November 9, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29129574/primary-aldosteronism-and-cardiovascular-risk-before-and-after-treatment
#4
John W Funder
No abstract text is available yet for this article.
November 9, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29128332/research-digest-hypoglycaemia-and-glucose-variability
#5
Naveed Sattar, David Preiss
No abstract text is available yet for this article.
November 8, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29104158/moderate-salt-restriction-with-or-without-paricalcitol-in-type-2-diabetes-and-losartan-resistant-macroalbuminuria-proceed-a-randomised-double-blind-placebo-controlled-crossover-trial
#6
Aneliya Parvanova, Matias Trillini, Manuel A Podestà, Ilian Petrov Iliev, Barbara Ruggiero, Manuela Abbate, Annalisa Perna, Francesco Peraro, Olimpia Diadei, Nadia Rubis, Flavio Gaspari, Fabiola Carrara, Nadia Stucchi, Antonio Belviso, Antonio C Bossi, Roberto Trevisan, Giuseppe Remuzzi, Martin de Borst, Piero Ruggenenti
BACKGROUND: Macroalbuminuria predicts renal and cardiovascular events in patients with type 2 diabetes. We aimed to assess the albuminuria-lowering effects of salt restriction, paricalcitol therapy, or both, in this population. METHODS: In this randomised, double-blind, placebo-controlled, crossover trial, we recruited adult patients with type 2 diabetes from six diabetology outpatient clinics in northern Italy, with 24 h albuminuria of more than 300 mg despite 100 mg per day losartan therapy, blood pressure of less than 140/90 mm Hg, serum creatinine concentration of less than 2 mg/dL, stable renal function on stable renin-angiotensin system inhibitor therapy with a fixed dose of losartan, parathyroid hormone concentration of 20 pg/mL to <110 pg/mL, serum calcium concentration of less than 9·5 mg/dL, and serum phosphate concentration of less than 5 mg/dL, who had been more than 80% compliant with placebo treatment during a 1 month placebo run-in...
November 2, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29104157/paricalcitol-and-albuminuria-tread-carefully
#7
Beatriz Fernandez-Fernandez, Alberto Ortiz
No abstract text is available yet for this article.
November 2, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29102566/cardiovascular-risk-factors-and-carotid-intima-media-thickness-in-young-adults-born-small-for-gestational-age-after-cessation-of-growth-hormone-treatment-a-5-year-longitudinal-study
#8
Manouk van der Steen, Gerthe F Kerkhof, Carolina C J Smeets, Anita C S Hokken-Koelega
BACKGROUND: Growth hormone treatment reduces blood pressure and lipid concentrations. We assessed long-term changes in blood pressure, lipid concentrations, and carotid intima media thickness over a 5-year period after cessation of growth hormone treatment in adults born small for gestational age. METHODS: We did a longitudinal observational study at a medical centre in the Netherlands between April 1, 2004, and April 1, 2016. We included adults born small for gestational age who were treated with growth hormone (1 mg/m(2) per day); treatment started during childhood until adult height...
November 1, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29102565/cardiovascular-risk-after-cessation-of-growth-hormone-treatment-in-people-born-small-for-gestational-age
#9
Rosario Pivonello, Carolina Di Somma, Annamaria Colao
No abstract text is available yet for this article.
November 1, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29092776/top-ten-research-priorities-for-type-2-diabetes-results-from-the-diabetes-uk-james-lind-alliance-priority-setting-partnership
#10
LETTER
Sarah Finer, Paul Robb, Katherine Cowan, Ann Daly, Elizabeth Robertson, Andrew Farmer
No abstract text is available yet for this article.
October 27, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29102433/effect-of-vitamin-d-supplementation-on-non-skeletal-disorders-a-systematic-review-of-meta-analyses-and-randomised-trials
#11
REVIEW
Philippe Autier, Patrick Mullie, Alina Macacu, Miruna Dragomir, Magali Boniol, Kim Coppens, Cécile Pizot, Mathieu Boniol
Randomised trials reported up to Dec 31, 2012, did not confirm that vitamin D supplementation could protect from non-skeletal health conditions affecting adults, as was expected on the basis of data from observational studies. To examine whether the more recently published meta-analyses and trials would change past conclusions, we systematically reviewed meta-analyses of vitamin D supplementation and non-skeletal disorders published between Jan 1, 2013, and May 31, 2017, that included study participants of all ages, including pregnant women...
October 25, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29102432/follicular-thyroid-cancer-and-h%C3%A3-rthle-cell-carcinoma-challenges-in-diagnosis-treatment-and-clinical-management
#12
REVIEW
Giorgio Grani, Livia Lamartina, Cosimo Durante, Sebastiano Filetti, David S Cooper
Follicular thyroid cancer is the second most common differentiated thyroid cancer histological type and has been overshadowed by its more common counterpart-papillary thyroid cancer-despite its unique biological behaviour and less favourable outcomes. In this Review, we comprehensively review the literature on follicular thyroid cancer to provide an evidence-based guide to the management of these tumours, to highlight the lack of evidence behind guideline recommendations, and to identify changes and challenges over the past decades in diagnosis, prognosis, and treatment...
October 25, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29079253/how-can-we-optimise-diabetes-care-in-real-world-practice
#13
Juliana C N Chan
No abstract text is available yet for this article.
October 24, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29079252/effect-of-an-intensified-multifactorial-intervention-on-cardiovascular-outcomes-and-mortality-in-type-2-diabetes-j-doit3-an-open-label-randomised-controlled-trial
#14
Kohjiro Ueki, Takayoshi Sasako, Yukiko Okazaki, Masayuki Kato, Sumie Okahata, Hisayuki Katsuyama, Mikiko Haraguchi, Ai Morita, Ken Ohashi, Kazuo Hara, Atsushi Morise, Kazuo Izumi, Naoki Ishizuka, Yasuo Ohashi, Mitsuhiko Noda, Takashi Kadowaki
BACKGROUND: Limited evidence suggests that multifactorial interventions for control of glucose, blood pressure, and lipids reduce macrovascular complications and mortality in patients with type 2 diabetes. However, safe and effective treatment targets for these risk factors have not been determined for such interventions. METHODS: In this multicentre, open-label, randomised, parallel-group trial, undertaken at 81 clinical sites in Japan, we randomly assigned (1:1) patients with type 2 diabetes aged 45-69 years with hypertension, dyslipidaemia, or both, and an HbA1c of 6·9% (52·0 mmol/mol) or higher, to receive conventional therapy for glucose, blood pressure, and lipid control (targets: HbA1c <6·9% [52·0 mmol/mol], blood pressure <130/80 mm Hg, LDL cholesterol <120 mg/dL [or 100 mg/dL in patients with a history of coronary artery disease]) or intensive therapy (HbA1c <6·2% [44·3 mmol/mol], blood pressure <120/75 mm Hg, LDL cholesterol <80 mg/dL [or 70 mg/dL in patients with a history of coronary artery disease])...
October 24, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29066097/correction-to-lancet-diabetes-endocrinol-2017-published-online-sept-29-http-dx-doi-org-10-1016-s2213-8587-17-30239-5
#15
(no author information available yet)
No abstract text is available yet for this article.
October 20, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29066096/interventions-to-prevent-global-childhood-overweight-and-obesity-a-systematic-review
#16
REVIEW
Sara N Bleich, Kelsey A Vercammen, Laura Y Zatz, Johannah M Frelier, Cara B Ebbeling, Anna Peeters
In view of the prevalence, health consequences, and costs of childhood obesity, there has been substantial interest in identifying effective interventions to prevent excess weight gain in young people. In this systematic review, we expand on previous reviews of obesity prevention interventions by including recent studies (until May 23, 2017) from all parts of the world. We searched MEDLINE, Embase, CINAHL Plus, Web of Science, CAB Abstracts, and PAIS Index and included randomised controlled trials, quasi-experimental studies, or natural experiments with: (1) a control group; (2) minimum follow-up of 12 months for community-based and home-based interventions or 6 months for school-based and preschool-based interventions; and (3) a primary outcome of BMI, BMI Z score, BMI percentile, body fat percentage, skinfold thickness, waist circumference, or prevalence of overweight or obesity...
October 20, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29050900/bone-and-mineral-disorders-in-chronic-kidney-disease-implications-for-cardiovascular-health-and-ageing-in-the-general-population
#17
REVIEW
Adrian Covic, Marc Vervloet, Ziad A Massy, Pablo Ureña Torres, David Goldsmith, Vincent Brandenburg, Sandro Mazzaferro, Pieter Evenepoel, Jordi Bover, Mugurel Apetrii, Mario Cozzolino
The patient with chronic kidney disease (CKD) represents an extreme model for arteriosclerosis, vascular calcification, and bone disorders, all of which are also associated with ageing in the general population. These pathological features are also relevant to other common chronic health disorders such as diabetes, and chronic inflammatory and cardiovascular diseases. Although management and interventions for these major risk factors are now incorporated into most public health guidelines (eg, smoking cessation and control of bodyweight and blood pressure, as well as glucose and cholesterol concentrations), some residual cardiovascular risk is not reduced by implementation of these interventions...
October 16, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29032078/efficacy-and-safety-of-once-monthly-pasireotide-in-cushing-s-disease-a-12-month-clinical-trial
#18
André Lacroix, Feng Gu, Wilson Gallardo, Rosario Pivonello, Yerong Yu, Przemysław Witek, Marco Boscaro, Roberto Salvatori, Masanobu Yamada, Libuse Tauchmanova, Michael Roughton, Shoba Ravichandran, Stephan Petersenn, Beverly M K Biller, John Newell-Price
BACKGROUND: Cushing's disease is a rare debilitating endocrine disorder for which few prospective interventional studies have been done. We report results of the first phase 3 trial assessing long-acting intramuscular pasireotide in patients with Cushing's disease. METHODS: In this phase 3 clinical trial we recruited patients aged 18 years or older with persistent, recurrent, or de-novo (non-surgical candidates) Cushing's disease who had a mean urinary free cortisol (mUFC) concentration (from three 24 h samples) of 1·5-5·0 times the upper limit of normal (ULN), a normal or greater than normal morning plasma adrenocorticotropic hormone concentration, and a pituitary source of Cushing's syndrome, from 57 sites across 19 countries...
October 12, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29032080/is-the-new-treatment-for-cushing-s-disease-too-sweet
#19
Ashley Grossman
No abstract text is available yet for this article.
October 11, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29032079/omega-6-fatty-acid-biomarkers-and-incident-type-2-diabetes-pooled-analysis-of-individual-level-data-for-39%C3%A2-740-adults-from-20-prospective-cohort-studies
#20
Jason H Y Wu, Matti Marklund, Fumiaki Imamura, Nathan Tintle, Andres V Ardisson Korat, Janette de Goede, Xia Zhou, Wei-Sin Yang, Marcia C de Oliveira Otto, Janine Kröger, Waqas Qureshi, Jyrki K Virtanen, Julie K Bassett, Alexis C Frazier-Wood, Maria Lankinen, Rachel A Murphy, Kalina Rajaobelina, Liana C Del Gobbo, Nita G Forouhi, Robert Luben, Kay-Tee Khaw, Nick Wareham, Anya Kalsbeek, Jenna Veenstra, Juhua Luo, Frank B Hu, Hung-Ju Lin, David S Siscovick, Heiner Boeing, Tzu-An Chen, Brian Steffen, Lyn M Steffen, Allison Hodge, Gudny Eriksdottir, Albert V Smith, Vilmunder Gudnason, Tamara B Harris, Ingeborg A Brouwer, Claudine Berr, Catherine Helmer, Cecilia Samieri, Markku Laakso, Michael Y Tsai, Graham G Giles, Tarja Nurmi, Lynne Wagenknecht, Matthias B Schulze, Rozenn N Lemaitre, Kuo-Liong Chien, Sabita S Soedamah-Muthu, Johanna M Geleijnse, Qi Sun, William S Harris, Lars Lind, Johan Ärnlöv, Ulf Riserus, Renata Micha, Dariush Mozaffarian
BACKGROUND: The metabolic effects of omega-6 polyunsaturated fatty acids (PUFAs) remain contentious, and little evidence is available regarding their potential role in primary prevention of type 2 diabetes. We aimed to assess the associations of linoleic acid and arachidonic acid biomarkers with incident type 2 diabetes. METHODS: We did a pooled analysis of new, harmonised, individual-level analyses for the biomarkers linoleic acid and its metabolite arachidonic acid and incident type 2 diabetes...
October 11, 2017: Lancet Diabetes & Endocrinology
journal
journal
47944
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"